Estetrol/Drospirenone (Nextstellis) - Off-Label for Perimenopause

About

Nextstellis is a novel combined oral contraceptive containing estetrol, a native estrogen with selective activity, and drospirenone. While FDA-approved for contraception, it may be prescribed off-label to manage perimenopausal symptoms in appropriate candidates.

Efficacy

Contains estetrol, a native estrogen with selective tissue activity that may provide better tolerability than other estrogens

Targets Symptoms